揭示 UPF3B 在肝细胞癌中的作用:潜在的治疗目标。

IF 4.5 2区 医学 Q1 ONCOLOGY
Cancer Science Pub Date : 2024-06-18 DOI:10.1111/cas.16240
Bowen Hou, Min Shu, Chenghao Liu, Yunfeng Du, Cuicui Xu, Huijiao Jiang, Jun Hou, Xueling Chen, Lianghai Wang, Xiangwei Wu
{"title":"揭示 UPF3B 在肝细胞癌中的作用:潜在的治疗目标。","authors":"Bowen Hou,&nbsp;Min Shu,&nbsp;Chenghao Liu,&nbsp;Yunfeng Du,&nbsp;Cuicui Xu,&nbsp;Huijiao Jiang,&nbsp;Jun Hou,&nbsp;Xueling Chen,&nbsp;Lianghai Wang,&nbsp;Xiangwei Wu","doi":"10.1111/cas.16240","DOIUrl":null,"url":null,"abstract":"<p>RNA-binding proteins can regulate nucleotide metabolism and gene expression. UPF3B regulator of nonsense mediated mRNA decay (UPF3B) exhibits dysfunction in cancers. However, its role in the progression of hepatocellular carcinoma (HCC) is still insufficiently understood. Here, we found that UPF3B was markedly upregulated in HCC samples and associated with adverse prognosis in patients. UPF3B dramatically promoted HCC growth both in vivo and in vitro. Mechanistically, UPF3B was found to bind to <i>PPP2R2C</i>, a regulatory subunit of PP2A, boosting its mRNA degradation and activating the PI3K/AKT/mTOR pathway. E2F transcription factor 6 (E2F6) directly binds to the UPF3B promoter to facilitate its transcription. Together, the E2F6/UPF3B/PPP2R2C axis promotes HCC growth through the PI3K/AKT/mTOR pathway. Hence, it could be a promising therapeutic target for treating HCC.</p>","PeriodicalId":9580,"journal":{"name":"Cancer Science","volume":null,"pages":null},"PeriodicalIF":4.5000,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11309952/pdf/","citationCount":"0","resultStr":"{\"title\":\"Unveiling the role of UPF3B in hepatocellular carcinoma: Potential therapeutic target\",\"authors\":\"Bowen Hou,&nbsp;Min Shu,&nbsp;Chenghao Liu,&nbsp;Yunfeng Du,&nbsp;Cuicui Xu,&nbsp;Huijiao Jiang,&nbsp;Jun Hou,&nbsp;Xueling Chen,&nbsp;Lianghai Wang,&nbsp;Xiangwei Wu\",\"doi\":\"10.1111/cas.16240\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>RNA-binding proteins can regulate nucleotide metabolism and gene expression. UPF3B regulator of nonsense mediated mRNA decay (UPF3B) exhibits dysfunction in cancers. However, its role in the progression of hepatocellular carcinoma (HCC) is still insufficiently understood. Here, we found that UPF3B was markedly upregulated in HCC samples and associated with adverse prognosis in patients. UPF3B dramatically promoted HCC growth both in vivo and in vitro. Mechanistically, UPF3B was found to bind to <i>PPP2R2C</i>, a regulatory subunit of PP2A, boosting its mRNA degradation and activating the PI3K/AKT/mTOR pathway. E2F transcription factor 6 (E2F6) directly binds to the UPF3B promoter to facilitate its transcription. Together, the E2F6/UPF3B/PPP2R2C axis promotes HCC growth through the PI3K/AKT/mTOR pathway. Hence, it could be a promising therapeutic target for treating HCC.</p>\",\"PeriodicalId\":9580,\"journal\":{\"name\":\"Cancer Science\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2024-06-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11309952/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Science\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/cas.16240\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Science","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cas.16240","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

RNA 结合蛋白可调节核苷酸代谢和基因表达。UPF3B无义介导mRNA衰变调节蛋白(UPF3B)在癌症中表现出功能障碍。然而,人们对其在肝细胞癌(HCC)进展过程中的作用仍不甚了解。在这里,我们发现 UPF3B 在 HCC 样本中明显上调,并与患者的不良预后相关。UPF3B 在体内和体外都能显著促进 HCC 的生长。研究发现,UPF3B与PPP2A的调控亚基PPP2R2C结合,促进其mRNA降解并激活PI3K/AKT/mTOR通路。E2F转录因子6(E2F6)直接与UPF3B启动子结合,促进其转录。E2F6/UPF3B/PPP2R2C轴共同通过PI3K/AKT/mTOR途径促进HCC的生长。因此,它可能是治疗 HCC 的一个很有前景的治疗靶点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Unveiling the role of UPF3B in hepatocellular carcinoma: Potential therapeutic target

Unveiling the role of UPF3B in hepatocellular carcinoma: Potential therapeutic target

Unveiling the role of UPF3B in hepatocellular carcinoma: Potential therapeutic target

RNA-binding proteins can regulate nucleotide metabolism and gene expression. UPF3B regulator of nonsense mediated mRNA decay (UPF3B) exhibits dysfunction in cancers. However, its role in the progression of hepatocellular carcinoma (HCC) is still insufficiently understood. Here, we found that UPF3B was markedly upregulated in HCC samples and associated with adverse prognosis in patients. UPF3B dramatically promoted HCC growth both in vivo and in vitro. Mechanistically, UPF3B was found to bind to PPP2R2C, a regulatory subunit of PP2A, boosting its mRNA degradation and activating the PI3K/AKT/mTOR pathway. E2F transcription factor 6 (E2F6) directly binds to the UPF3B promoter to facilitate its transcription. Together, the E2F6/UPF3B/PPP2R2C axis promotes HCC growth through the PI3K/AKT/mTOR pathway. Hence, it could be a promising therapeutic target for treating HCC.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Cancer Science
Cancer Science 医学-肿瘤学
自引率
3.50%
发文量
406
审稿时长
2 months
期刊介绍: Cancer Science (formerly Japanese Journal of Cancer Research) is a monthly publication of the Japanese Cancer Association. First published in 1907, the Journal continues to publish original articles, editorials, and letters to the editor, describing original research in the fields of basic, translational and clinical cancer research. The Journal also accepts reports and case reports. Cancer Science aims to present highly significant and timely findings that have a significant clinical impact on oncologists or that may alter the disease concept of a tumor. The Journal will not publish case reports that describe a rare tumor or condition without new findings to be added to previous reports; combination of different tumors without new suggestive findings for oncological research; remarkable effect of already known treatments without suggestive data to explain the exceptional result. Review articles may also be published.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信